Compile Data Set for Download or QSAR
maximum 50k data
Found 9 Enz. Inhib. hit(s) with all data for assayid = 3 entry = 7878
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM50354578(BUPRENORPHINE | US10752592, Compound buprenorphine...)
Affinity DataKi:  0.0400nM ΔG°:  -59.3kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222959(US9315514, 3)
Affinity DataKi:  0.120nM ΔG°:  -56.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222960(US9315514, 4)
Affinity DataKi:  0.190nM ΔG°:  -55.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222963(US9315514, 11)
Affinity DataKi:  0.440nM ΔG°:  -53.4kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222961(US9315514, 5)
Affinity DataKi:  0.720nM ΔG°:  -52.2kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222962(US9315514, 6)
Affinity DataKi:  4.61nM ΔG°:  -47.6kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222965(US9315514, 8)
Affinity DataKi:  7.22nM ΔG°:  -46.5kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222964(US9315514, 12)
Affinity DataKi:  30.1nM ΔG°:  -42.9kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetKappa-type opioid receptor(Homo sapiens (Human))
Rhodes Technologies

US Patent
LigandPNGBDBM222966(US9315514, 7)
Affinity DataKi:  757nM ΔG°:  -34.9kJ/molepH: 7.4 T: 2°CAssay Description:Radioligand dose displacement assays used 0.4 nM [3H]-U69,593 (GE Healthcare, Piscataway, N.J.; 40 Ci/mmole) with 15 μg membrane protein (recombin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent